Fig. 1 (abstract P83).From: 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part OneCancer prevalences in the PD-L1(+) and CD8(+) low and high groups. Prevalences of seven cancer indications (see inset, with number of patients), grouped by classification into PD-L1(+) and CD8(+) low and high tile percentage tumors. The indications were sorted with respect to decreasing TMB as defined in [3]Back to article page